Dosing Study of Cranberry Capsules for the Prevention of Bacteriuria in Nursing Home Residents

NCT ID: NCT01033383

Last Updated: 2013-08-15

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-12-31

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will investigate whether there is a particular dose of cranberry capsules that is effective in preventing the occurrence of urinary tract infections in females at least 65 years of age or older who live in a nursing home and who have a history of urinary tract infections. The Yale research team will be enrolling 80 subjects in total over several nursing home locations within Connecticut.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Each subject was enrolled after providing a baseline urine specimen. Cranberry/placebo capsules were consumed for 30 days. Urine specimens were obtained weekly for 4 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bacteriuria

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

3 placebo capsules

3 placebo capsules qd

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

36 milligram (mg) placebo capsule taken before quiet hours of sleep (qhs).

1 cranberry capsule & 2 placebo capsules

1 active cranberry capsule and 2 placebo capsules qd

Group Type EXPERIMENTAL

Placebo

Intervention Type DIETARY_SUPPLEMENT

36 milligram (mg) placebo capsule taken before quiet hours of sleep (qhs).

Cranberry Capsule

Intervention Type DIETARY_SUPPLEMENT

36 milligram (mg) cranberry capsule, taken before quiet hours of sleep (qhs).

2 cranberry capsules & 1 placebo capsule

2 active cranberry capsules and 1 placebo capsules qd

Group Type EXPERIMENTAL

Placebo

Intervention Type DIETARY_SUPPLEMENT

36 milligram (mg) placebo capsule taken before quiet hours of sleep (qhs).

Cranberry Capsule

Intervention Type DIETARY_SUPPLEMENT

36 milligram (mg) cranberry capsule, taken before quiet hours of sleep (qhs).

3 cranberry capsules

3 active cranberry capsules qd

Group Type EXPERIMENTAL

Cranberry Capsule

Intervention Type DIETARY_SUPPLEMENT

36 milligram (mg) cranberry capsule, taken before quiet hours of sleep (qhs).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

36 milligram (mg) placebo capsule taken before quiet hours of sleep (qhs).

Intervention Type DIETARY_SUPPLEMENT

Cranberry Capsule

36 milligram (mg) cranberry capsule, taken before quiet hours of sleep (qhs).

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ellura

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female nursing home residents 65 years of age or older with history of urinary tract infection within the past year.

Exclusion Criteria

* residents that are not expected to be in the nursing home for at least one month (i.e., short term rehabilitation, pending discharge, terminal \[life expectancy \< 1 month\]);
* residents who are on chronic suppressive antibiotic or anti-infective (i.e., mandelamine) therapy for recurrent UTI;
* residents with end stage renal disease on dialysis (they do not regularly produce urine);
* residents unable to produce a baseline clean catch urine specimen for collection;
* residents on warfarin therapy because of a potential interaction of warfarin and cranberry juice;
* residents with a history of nephrolithiasis because cranberry may increase the risk of nephrolithiasis.
Minimum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute on Aging (NIA)

NIH

Sponsor Role collaborator

National Center for Research Resources (NCRR)

NIH

Sponsor Role collaborator

Yale University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Manisha Juthani-Mehta, MD

Role: PRINCIPAL_INVESTIGATOR

Yale University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Northbridge Health Care Center

Bridgeport, Connecticut, United States

Site Status

Sheriden Woods Health Care Center

Bristol, Connecticut, United States

Site Status

The Carolton Chronic and Convalescent Hospital

Fairfield, Connecticut, United States

Site Status

Glastonbury Health Care Center

Glastonbury, Connecticut, United States

Site Status

Middlesex Health Care Center

Middletown, Connecticut, United States

Site Status

Wadsworth Glen Health Care and Rehabilitation Center

Middletown, Connecticut, United States

Site Status

Beacon Brook Health Care Center

Naugatuck, Connecticut, United States

Site Status

Laurel Ridge Health Care Center

Ridgefield, Connecticut, United States

Site Status

Shady Knoll Health Center

Seymour, Connecticut, United States

Site Status

Litchfield Woods Health Care Center

Torrington, Connecticut, United States

Site Status

Maefair Health Care Center

Trumbull, Connecticut, United States

Site Status

Masonicare Health Center

Wallingford, Connecticut, United States

Site Status

Abbott Terracee Health Center

Waterbury, Connecticut, United States

Site Status

Saint Mary Home

West Hartford, Connecticut, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Bianco L, Perrelli E, Towle V, Van Ness PH, Juthani-Mehta M. Pilot randomized controlled dosing study of cranberry capsules for reduction of bacteriuria plus pyuria in female nursing home residents. J Am Geriatr Soc. 2012 Jun;60(6):1180-1. doi: 10.1111/j.1532-5415.2012.03976.x. No abstract available.

Reference Type RESULT
PMID: 22690994 (View on PubMed)

Williams G, Stothart CI, Hahn D, Stephens JH, Craig JC, Hodson EM. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2023 Nov 10;11(11):CD001321. doi: 10.1002/14651858.CD001321.pub7.

Reference Type DERIVED
PMID: 37947276 (View on PubMed)

Williams G, Hahn D, Stephens JH, Craig JC, Hodson EM. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2023 Apr 17;4(4):CD001321. doi: 10.1002/14651858.CD001321.pub6.

Reference Type DERIVED
PMID: 37068952 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

K23AG028691-01A2

Identifier Type: NIH

Identifier Source: secondary_id

View Link

UL1RR024139

Identifier Type: NIH

Identifier Source: secondary_id

View Link

KL2RR024138

Identifier Type: NIH

Identifier Source: secondary_id

View Link

0908005581

Identifier Type: -

Identifier Source: org_study_id